Orchid Pharma Ltd

- Orchid Pharma does not anticipate any large capital expenditure for general growth apart from already announced projects like Cefiderocol and 7ACA. - There is no explicit mention of plans for new fundraising through debt or equity in the discussed period. - The company is focusing on stabilizing new projects and optimizing costs to improve margins. - Any future expansion, especially related to increased capacity (e.g., for the new antimicrobial product), would depend on market demand but is currently considered too early to quantify financial needs. - The firm is leveraging existing infrastructure and capacity with minimal additional investment planned. - Discussions with government schemes (PLI, GST benefits, interest subvention) help reduce financing burdens. Overall, no immediate plans for fresh fundraises were disclosed as of February 2024.

- Current and future capex includes: - Rs.600 Crores investment in the 7ACA project (includes entire project outlay, working capital and fixed assets). - $10 million to $15 million investment planned for the Cefiderocol project. - Setting up a new sterile block commissioned in Nov 2023, targeting optimal utilization in next 6-12 months. - Capacity reconfiguration for oral products to shift from low-margin to higher-margin products, expected completion by end of H1 FY2025. - Backward integration for 7ACA, with engineering phase completed and pilot plant trials ongoing. - Plant designed to allow capacity increase up to three times with minimal additional investment depending on demand. - No need for large capex for general growth beyond announced projects like Cefiderocol and 7ACA.

Future growth expectations for Orchid Pharma as per the provided transcript: - Anticipated quarter-on-quarter and year-on-year revenue growth of 20-25% over the next few years. - Growth driven by new customers, new markets, and new product launches, including off-patent products like Ceftazidime Avibactam. - Launch of new hospital sales division (Orchid Antimicrobial Solutions) expected in the next 1-2 quarters to boost hospital business revenues from FY2025. - Capacity optimization underway, including oral capacity rejig expected by end of H1 FY2025. - No large capital expenditures expected beyond ongoing projects (e.g., Cefiderocol, 7ACA). - Anticipated exponential growth for newly approved products such as Enmetazobactam in Europe and US starting Q1 next financial year. - Potential increase in capacity by debottlenecking without major capex, supporting growth. - Expansion plans with partners for antimicrobial products targeting 135 countries, especially LMICs.

- Orchid Pharma targets a long-term year-on-year revenue growth of **20% to 25%**. - EBITDA margins are expected to remain stable around **40% plus/minus 2%**. - Operating margins for specific projects like 7ACA are anticipated to be around **10%**, potentially allowing payback within 3 years post-operations. - The company expects **high teens EBITDA margins** in the long term. - Growth drivers include new product launches (e.g., Enmetazobactam, Cefiderocol), geographic expansion (US, Europe, LMICs), and improved domestic & export markets. - Planned capacity expansions and debottlenecking efforts support scaling revenues without major additional capex. - The hospital business and antimicrobial solutions division are expected to begin contributing commercially starting FY2025. - Profit after tax showed a substantial increase recently, indicating positive momentum in earnings growth.

- The transcript does not explicitly mention the current or expected order book or pending orders for Orchid Pharma. - Discussions focus on capacity, growth, product launches, and collaborations (notably with GARDP and Shionogi). - Capacity setup for Cefiderocol at around 1 million vials initially, with scalable design to triple capacity if demand grows. - Antimicrobial Solutions division is being developed, with expected launch in next 1-2 quarters. - Growth is driven by multiple markets and new products; no specific order volume or backlog data shared. - Launch of Cefiderocol expected in India in second half of 2026, but regulatory pathways and commercialization strategies are still being finalized. - Pricing and marketing strategies are controlled by GARDP/Shionogi, affecting order volumes indirectly. - Overall, no concrete numbers on order book or pending orders were provided during the call.